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Trabectedin has been approved for second-line treatment of soft tissue sarcomas. However, its efficacy to target sarcoma
initiating cells has not been addressed yet. Here, we used pioneer models of myxoid/round cell liposarcoma (MRCLS) and
undifferentiatedpleomorphicsarcoma (UPS)developed fromtransformedhumanmesenchymal stromal/stemcells (MSCs)
to evaluate the effect of trabectedin in the cell type responsible for initiating sarcomagenesis and their derived cancer stem
cells (CSC) subpopulations. We found that low nanomolar concentrations of trabectedin efficiently inhibited the growth of
sarcoma-initiating cells, induced cell cycle arrest, DNA damage and apoptosis. Interestingly, trabectedin treatment
repressed the expression ofmultiple genes responsible for the development of the CSC phenotype, including pluripotency
factors, CSCmarkers and related signaling pathways. Accordingly, trabectedin induced apoptosis and reduced the survival
of CSC-enriched tumorsphere cultures with the same efficiency that inhibits the growth of bulk tumor population. In vivo,
trabectedin significantly reduced the mitotic index of MRCLS xenografts and inhibited tumor growth at a similar extent to
that observed in doxorubicin-treated tumors. Combination of trabectedin with campthotecin (CPT), a chemotherapeutic
drug that shows a robust anti-tumor activity when combined with alkylating agents, resulted in a very strong synergistic
inhibition of tumor cell growth and highly increased DNA damage and apoptosis induction. Importantly, the enhanced anti-
tumor activity of this combinationwas also observed in CSC subpopulations. These data suggest that trabectedin and CPT
combinationmay constitute a novel strategy to effectively target both the cell-of-origin andCSCsubpopulations in sarcoma.
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Recent advances in sarcoma genomics have contributed to the
development of new therapeutic strategies. However, cytotoxic drugs
like doxorubicin alone or in combination with ifosfamide, remain as
the most utilized agents for first-line treatment of soft tissue sarcomas
despite their limited clinical response [1]. A hypothesis to explain the
resistance of sarcomas to chemotherapy is the existence of
subpopulations of drug-resistant cancer stem cells (CSCs), considered
to be responsible for relapses and metastasis. It has been recently
established that transformed MSCs and/or their immediate lineage
progenitors are the most likely cell-of-origin for sarcomas [2,3].
Accordingly, many efforts have been undertaken to produce models of
sarcomas based on MSCs transformed with relevant oncogenic events.
This kind of models constitutes unparalleled systems to unravel the
mechanisms underlying sarcomagenesis from the cell of origin, to explore
the evolution of CSCs subpopulations and to search for CSC-specific
therapies. In this regard, we have recently established and characterized
pioneer models of undifferentiated pleomorphic sarcoma (UPS) and
myxoid/round cell liposarcoma (MRCLS) developed from sequentially
mutated human bone marrow-derived MSCs (hBMSCs) [4–6].
Trabectedin (ET-743, Yondelis) is a marine alkaloid originally
isolated from the tunicate ecteinascidia turbinate. This compound has
shown a consistent activity in soft tissue sarcomas (STS) in several
clinical trials. Although, it has not demonstrated an objective
advantage over first-line standard doxorubicin-based therapy, trabec-
tedin has been approved for the treatment of adult patients with
advanced STS, after failure of anthracyclines and ifosfamide, or those
who are unsuited to receive these agents [1,7,8]. Trabectedin presents
a complex mechanism of action affecting several key processes in both
tumor cells and microenvironment [8–10]. Unlike classical alkylating
drugs, trabectedin binds covalently to specific triplets of the DNA
minor groove leading to a distortion of the double helix structure.
These DNA adducts interfere with the binding of several
transcription factors to their specific promoter elements. Specifically,
trabectedin blocks the transcriptional activity of oncogenic transcrip-
tion factors such as FUS-CHOP or EWS-FLI-1, which are products
of characteristic chromosomal translocations respectively observed in
MRCLS and Ewing's sarcoma [9,11–13]. Indeed, trabectedin is
particularly efficient in MRCLS patients [14]. In MRCLS pre-clinical
models, FUS-CHOP activity inhibition by trabectedin promotes
adipogenic differentiation [12,15,16] and inhibits the production of
inflammatory mediators by the tumor cells [17]. The structural
changes induced by trabectedin cannot be resolved by the nucleotide
excision repair (NER) mechanism, which instead are involved in the
formation of double strand breaks (DSB) that could be repaired by
homologous recombination repair [18–21]. Therefore, trabectedin
exhibits reduced efficacy in cells deficient in NER, while it is more
potent in homologous recombination repair-deficient cells [22–24].
The formation trabectedin-DNA adducts are also able to trap DNA
topoisomerase I, which normally introduce single strand breaks (SSB)
to relax DNA supercoiling during replication and transcription. Thus,
trabectedin-induced topisomerase I-DNA complexes mediate SSB
formation that may evolve to DSB [25].
Several combination strategies have been tested in order to increase the
therapeutic index of trabectedin in sarcomas. Many of these strategies are
based on the combination with compounds that induce DNA damage
while also interfering with DNA damage repair mechanisms, such as
doxorubicin, cisplatin, PARP inhibitors or campthotecins [1,8,21,26–28].
Campthotecin (CPT) and its derivatives irinotecan and topotecan arechemotherapeutic drugs with proved activity against several types of
sarcoma [29–32]. CPT targets DNA topoisomerase I and inhibits its
resealing activity leading to the stabilization of the transiently-generated
SSBwhich can be converted into toxicDSB by collision with replication
or transcription complexes [33,34].
In this report, we show that trabectedin inhibits tumor cell growth
initiated by cell-of-origin models of MRCLS and UPS, represses the
expression of important genes associated to the CSC phenotype and
targets CSC subpopulations at rates comparable to that of non-CSC
subpopulations. Furthermore, we show that trabectedin efficacy is
synergistically increased by combination with CPT.
Materials and Methods
Cell Types and Drugs
Previously developed transformed human BM-MSCs lines (Table S1
and Supplemental information) were cultured as previously described
[4–6,35]. Trabectedin and camptothecin were obtained from Pharma-
Mar (Madrid, Spain) and Sigma (St Louis, MO), respectively
(Supplemental information). All experimental protocols have been
performed in accordance with institutional review board guidelines and
were approved by the Institutional Ethics Committee of the Hospital
Universitario Central de Asturias. All samples from human origin were
obtained upon signed informed consent.
Western Blot
Whole cell protein extraction and Western blot analysis were
performed as previously described [36]. Antibodies used are described
in Supplemental information.
RT-qPCR Assays
The Human Cancer Stem Cells RT2 Profiler PCR Array
(PAHS-176-Z; SA Biosciences, Qiagen Iberia, Madrid, Spain) was
used to analyze the expression of 84 genes linked to CSCs properties
according to the manufacturer instructions and as described before
[37,38]. A complete data set including gene information and
experimentally obtained Ct values is presented in Table S2.
Cell Viability Assays
The viability of all cell lines in the presence and absence of drugs was
determined using the cell proliferation reagent WST-1 (Roche,
Mannheim, Germany) as described before [38]. In dose–response
experiments cells were treated for 72 hours and all the assayed
conditions contain the same concentration of drug solvent (DMSO).
The concentration of half-maximal inhibition of viability (IC50) for
each treatment was determined by non-linear regression. The existence
of synergy in drug combinations was determined by calculating the
combination index (CI) according to the Chou and Talalay method
using CompuSyn software (ComboSyn) [39]. CI vs. the fraction
affected (Fa) plots were generated for six combinations of drugs at a fixed
ratio according to their IC50s. CI values indicate synergistic (b1),
additive (=1) and antagonistic (N1) drug interactions.
Tumorsphere Culture
Tumorsphere formation protocol and the analysis of the effects of
drugs on tumorsphere formation ability were previously described [38].
Immunofluorescence Staining
In immunofluorescence staining experiments in adherent cultures
(2-D) and tumorspheres (3-D) fixation, staining and mounting of the
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experimental conditions are described in Supplemental information.
Cell-cycle Analysis
Cell-cycle analysis of floating and adherent cells was carried out as
described previously [34].
Aldefluor Assay
ALDH activity was determined using the activated Aldefluor™ reagent
(Stem Cells Technologies, Grenoble, France) as previously reported [37].
Soft Agar Colony Formation Assay
A soft agar colony formation assay was carried out using the
CytoSelect™ 96-Well Cell Transformation Assay Kit (Cell Biolabs Inc.,
San Francisco, CA) as described [37] (Supplemental information).
Xenograft Experiments
Female NOD/SCID mice of 5–6 weeks old (Janvier Labs, St
Berthevin, France) were inoculated subcutaneously (s.c.) with 1×106
T5H–FC#1 cells. Once tumors reached 200–500 mm3, the mice
were randomly assigned to receive intra-venous (i.v.) treatments of
saline solution (control) or trabectedin at a dose of 0.15 mg/kg on
days 0, 7, 14, and 18. Mean tumor volume differences between
groups were determined using a caliper. Animals were sacrificed by
CO2 asphyxiation on day 19 after the start of treatments and the
tumors were extracted and weighed. The Student t test was performed
to determine the statistical significance between control and treated
groups. Survival was represented using Kaplan–Meier analysis and the
log-rank test to estimate significant differences among groups (PAST
3.01 software). Drug efficacy was expressed as the percentage tumor
growth inhibition (%TGI) calculated as previously reported [38]. All
animal research protocols were approved by the Animal Research
Ethical Committee of the University of Oviedo prior to the study.
Histological Analysis
Tumor samples were fixed in formol, embedded in paraffin, cut
into 4-μm sections, and stained with hematoxylin and eosin (H&E)
[40]. Quantification of mitosis was performed by counting the
number of mitotic figures per 10 high power fields (40×). Tumor
grade was analyzed in H&E-stained preparations using a variant of
the French Federation of Comprehensive Cancer Centers grading
system (Supplemental information).
Results
Antiproliferative Effects of Trabectedin
We have previously developed UPS (MSC-5H-GFP,
MSC-5H-O, T-5H-GFP#1 and T-5H-O cell lines) and
FUS-CHOP-expressing MRCLS models (MSC-5H-FC and
T-5H-FC#1 cell lines) using hBMSCs sequentially mutated with
up to six oncogenic events (see Table S1 and Supplemental
information for a description of these cell lines) [4–6]. First, in 72
hours-treatment dose–response experiments, we compared the
cytotoxic effect of trabectedin on these cell-of-origin models with
that observed inwild type hBMSCs and other tumor cell lines (Figure 1A).
Wild-type hBMSCs and the lung cancer cell line A-549 were
respectively fully and partially resistant to trabectedin. On the other
hand, the MRCLS cell line 402.91 was the most sensitive cell line. The
sarcoma-initiating cells MSC-5H-GFP, MSC-5H-FC, their
xenograft-derived cell lines T5H–GFP#1 and T5H–FC#1 and theMRCLS cell line 1765 were also sensitive to low nanomolar
concentrations of trabectedin, although display IC50 values between
five and ten times higher than the 402.91 cell line (Figure 1A). In
addition, time-course experiments showed a time-dependent decrease
in cell viability of the cell-of-origin models treated with 4 nM
trabectedin (Figure 1B). To further investigate the mechanism
underlying the antiproliferative effect of trabectedin, we examined the
effect of this drug on the cell cycle distribution, DNA damage induction
and apoptosis induction. Both MSC-5H-FC (Figure 1C) and
T-5H-FC#1 cells (Figure S1A) treated with 0.5 nM trabectedin
showed a slow transition through the S-phase followed by G2 arrest,
meanwhile cells treated with a higher concentration (2 nM) showed a
more stringent S-phase block and a consistent increment in the Sub-G1
apoptotic population at latter times. In addition, trabectedin was also a
potent inducer of DSBs in these cell lines as indicated by the
dose-dependent increase in both intranuclear H2AX foci and protein
levels after 1 hour treatment (Figure 1, D–F, Figure S1, B and C and
Figure S2). In line with these results, both UPSmodel (MSC-5H-GFP/
T5H–GFP#1) and MRCLS model (MSC-5H-FC/ T5H–FC#1) cell
types displayed a similar time-dependent apoptotic PARP cleavage after
trabectedin treatment (Figure 1G). Thus, trabectedin induced cell cycle
arrest and DNA damage followed by apoptotic cell death in cell-of-origin
sarcoma models.
Trabectedin Down-Regulates the Expression of Genes Associated
to the CSC Phenotype
To know how trabectedin affected the CSC phenotype in sarcoma
development, we performed RT-PCR in T-5H-FC#1 MRCLS-
forming cells treated for 24 h with 1 nM trabectedin to analyze the
expression of an array of 84 genes with well-known functions in
pluripotency, self-renewal, migration, metastasis, and signal transduc-
tion in CSCs as well as several CSC markers. Trabectedin led to
statistically significant changes (fold change ≥2; P b .05) in the
expression of 36 genes (Figure 2, A and B). Notably, this drug induced
the down-regulation of almost all the altered genes (3 up-regulated
genes and 33 down-regulated genes). These repressed genes included
various important pluripotency factors like SOX2, C-MYC, KLF4, and
BMI1, CSC markers in different types of tumors, including sarcomas,
like ABCG2, KIT/CD117, MUC1 and GATA3 and genes involved in
relevant stemness signaling pathways such as NOTCH signaling
(MALML1 and JAG1) orNFκB signaling (NFκB1 and IκBKB) among
others (Figure 2B). In striking contrast, we previously showed that after
the treatment of T5H–FC#1 cells with the chemotherapeutic drug
doxorubicin, commonly used in the treatment of soft tissue sarcomas,
most of the statistically altered CSC-related genes resulted up-regulated
(21 up-regulated genes and 9 down-regulated genes) [38]. Among the
doxorubicin-up-regulated genes there are relevant pluripotency factors
and/or CSC markers like NANOG, POU5F1/OCT3/4, THY1/
CD90, ALDH1A1, PROM1/CD133, KIT/CD117 or CD24 [38].
These data suggest that trabectedin treatment may disadvantage
the CSC phenotype in sarcomas.
Trabectedin Targets CSC Subpopulations In Vitro
All the sarcoma-initiating cells used in this study were able to form
tumorspheres with enhanced tumor formation ability, as previously
shown [37]. To test whether trabectedin may affect CSC viability,
MSC-5H-FC and T-5H-FC#1 cells were treated with increasing
concentrations of trabectedin for 72 h and then grown under CSC
culture conditions to assay the ability of trabectedin to inhibit the
Figure 1. Antiproliferative effects of trabectedin. (A-B) Cell viability (WST1 assay) measured after the treatment of the indicated cell lines
with increasing concentrations of trabectedin for 72 hours (A) or with 4 nM trabectedin for the indicated time-course (B). IC50 values for
each cell type are shown (A). (C) Time-course evolution of the cell cycle distribution of MSC-5H-FC cells treated with the indicated
concentrations of trabectedin. (D) Representative images of immunostaining experiments showing a dose-dependent increase in γH2AX
foci formation following 1 hour trabectedin treatment in MSC-5H-FC cells. Inset shows a magnification of a representative cell. Scale
bars = 50 μm. An enlarged color version of this panel is displayed as Figure S2. (E) Quantification of γH2AX foci was performed by
counting more than 200 cells in each condition. The percentage of cells presenting high level of DNA damage (N10 foci) is displayed. A
similar set of experiments for T-5H-FC#1 cells is presented as Figure S1, B and C. (F) Western blotting showing γH2AX protein levels after
the indicated trabectedin treatment. (G) Western blotting using an antibody to recognize normal and apoptotic-cleaved forms of PARP in
the indicated cell lines treated with 1 nM trabectedin for the indicated times. β-Actin levels were used as loading control in Western
blotting experiments. Error bars represent the standard deviation of at least 12 replicates from three independent experiments.
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number (Figure 3A) and viability (Figure 3B) of tumorspheres,
showing IC50 values similar to those obtained after the treatment of
adherent cultures (Figure 1A). These results suggest that trabectedin is
able to effectively target CSCs subpopulations (tumorsphere-forming
subpopulations) in vitro with the same efficiency that inhibits the
growth of bulk tumor population. To confirm the effect of
trabectedin on CSCs we directly treated already formed tumorspheres
with this drug for 72 hours [38]. After trabectedin treatment,
MSC-5H-FC and T5H–FC#1 tumorspheres were smaller and
displayed a disrupted and irregular morphology and the number
and viability of the tumorspheres dramatically decreased in a
dose-dependent fashion in both cell types (Figure 3, C–E). Consistent
with this findings trabectedin was able to induce dose-dependent
apoptosis in tumorsphere-forming cells, as shown by PARP apoptotic
cleavage induction in situ (Figure 3F). In fact, trabectedin inducedsimilar levels of apoptosis in bulk-adherent and CSC-tumorsphere
cultures as shown in dose–response and time-course experiments
(Figure 3, G–H). In addition, trabectedin caused a similar degree of
DNA damage in adherent and tumorsphere cultures as seen by the
increase in γH2AX levels (Figure 3I).
Tumorsphere cultures of these sarcoma models are highly enriched in
Aldefluor activity. Importantly, the subpopulation of T-5H-O cells with
high Aldefluor activity (ALDHhigh) displayed increased tumorigenic
properties, thus validating this activity as a CSCmarker in our cells [37].
To analyze the effect of trabectedin on this subpopulation of CSCs, we
isolated ALDHhigh and ALDHlow T-5H-O cells by flow cytometry and
put them back in adherent cultures. As expected, these subpopulations
showed relevant differences in Aldefluor activity (Figure 4A) and
expressed higher levels of the ALDH1 isoforms ALDH1A1 and
ALDH1A3 (Figure 4B). In addition, both subpopulations were equally
sensitive to 72 hours-treatment with increasing concentrations of
Figure 2. Changes in CSC-related gene expression induced by trabectedin. RNA isolated from T5H–FC#1 cells treated with the carrier
substance (DMSO) or with 1 nM trabectedin for 24 hours was used to analyze the expression of 84 CSC-related genes (RT2 Profiler™ PCR
Array System PAHS-176Z, Qiagen). (A) Scatter plot representing the expression values in control (DMSO) and trabectedin-treated cells for
each gene. Genes above and below the dashed lines are expressed more than two-fold up or down in treated versus untreated cells
respectively. (B) List of genes differentially expressed (fold change ≤2 or ≥2 and P value (two-sided Student t test) b 0.05) after
trabectedin treatment.
464 Trabectedin Targets Sarcoma Cancer Stem Cells Martinez-Cruzado et al. Neoplasia Vol. 19, No. 6, 2017trabectedin (Figure 4C). Even though the ability to form colonies in soft
agar, a surrogate in vitro transformation assay, was higher in ALDHhigh
cells, trabectedin pre-treatment robustly prevented colony formation in
both subpopulations (Figure 4D). Likewise, trabectedin pre-treatment
completely abolished the ability of both subpopulations to grow as
tumorspheres (Figure 4E). In line with these observations, trabectedin
induced apoptosis (PARP cleavage) and DNA damage (increase in
γH2AXprotein levels) with similar efficacy in ALDHhigh and ALDHlow
subpopulations (Figure 4B). Altogether these results support that
trabectedin could constitute an effective treatment to target both CSC
and non-CSC subpopulations in sarcoma.
Trabectedin Inhibits the Growth of MRCLS Xenografts
Trabectedin treatment caused an important tumor growth
inhibition in MRCLS xenografts originated from T-5H-FC#1 cells.
Compared to vehicle (saline buffer) treated group, trabectedin treated
mice (0.15 mg/kg on days 0, 7, 14, and 18) showed significant
differences in tumor volume as soon as 7 days after the beginning of
the treatment (Figure 5A). At later times, trabectedin-induced TGI
percentages rose up to 54.16%, and treated mice showed a significant
increase in survival (Figure 5, A and B). Likewise, tumor weights in
the control series doubled those of the trabectedin-treated series at the
end of the experiment (Figure 5C). Notably, trabectedin treatment
did not cause loss of weight (Figure 5D) or other adverse effects. The
anti-tumor activity of trabectedin is similar to that previously reported
after the treatment of T-5H-FC#1 xenografts with doxorubicin
(6 mg/kg on days 0, 7, and 14), although this treatment resulted toxic
at later time points [38] (see Figure S3 for a comparison of trabectedin
and doxorubicin treatments).
Histological examination of T-5H-FC#1 derived tumors showed
that trabectedin-treated tumors exhibited significantly lower mitotic
counts than untreated tumor samples (Figure 5, E and F).
Furthermore, tumors treated with trabectedin showed a significant
reduction in tumor grade (Figure 5G).Trabectedin and Camptothecin Combination Shows Synergistic
Cytotoxic Effect
In an effort to increase the anti-tumor effect of trabectedin in
sarcoma-initiating cells, we combined this drug with CPT. Since both
drugs are potent inducers of DSBs by two different mechanisms and
alkylating agents have been shown to increase the anti-tumor activity
of campthotecins [41,42] we hypothesized that they could synergize
to inhibit tumor cell growth.
MSC-5H-FC and T-5H-FC#1 cells were moderately sensitive to
CPT presenting IC50 values of 5.3 and 8.9 nM respectively (Figure
S4A). Combination of trabectedin with increasing concentrations of
CPT markedly increased the cytotoxicity of trabectedin in both cell
types even at very low concentrations of CPT (Figure 6, A and B). By
representing the data of the combination normalized to effect of CPT
alone we found that CPT 0.5 nM shifted the IC50 of trabectedin from
0.51 to 0.029 nM in MSC-5H-FC cells and from 0.55 to 0.017 nM
in T-5H-FC#1 cells (Figure 6, C and D). To test whether the
trabectedin and CPT combination has a synergistic cytotoxic effect
we calculated their CI using the CompuSyn software according to the
Chou-Talalay method [39]. In 72 hours-treatment experiments all
assayed constant ratio combinations showed CI values far below 1 in
both MSC-5H-FC and T-5H-FC#1 cells with CI values for ED50
combination doses of 0.041 and 0.024, respectively (Figure 6, E and F).
Therefore these data meet the criteria for very strong synergism (CI
b0.1) between these drugs. In line with this synergistic effect the
combination of low concentrations of trabectedin and CPT induced
significantly higher levels of γH2AX foci and protein levels and
apoptotic PARP cleavage than either drug alone (Figure 6, G–I
Figure S4B and Figure S5). Importantly pretreatment with the drug
combination was much more efficient in reducing the ability of
MSC-5H-FC and T-5H-FC#1 cells to grow tumorspheres than
trabectedin or CPT alone (Figure 6, J and K). In addition direct
treatment of the tumorspheres formed by both cell types with the
Figure 3. Trabectedin targets CSC-enriched tumorsphere cultures. (A-B) MSC-5H-FC and T-5H-FC#1 cell lines treated with the indicated
concentrations of trabectedin for 72 hours were grown in tumorsphere culture conditions for 10 days. After this period, the number
(represented as % of control) (A) and the cell viability (WST1 assay) (B) of tumorspheres formed were measured. (C-E) Counting (C), cell
viability (D) and representative images (E) of the tumorspheres remaining after the direct treatment of tumorsphere cultures of
MSC-5H-FC and T-5H-FC#1 cells with the indicated concentrations of trabectedin for 72 h. Scale bars = 200 μm. Error bars represent the
standard deviation of at least three independent experiments. F) Detection of cleaved PARP in GFP-positive T5H–FC#1 sarcospheres
treated with DMSO, or increasing concentrations of trabectedin for 72 h. Scale bars = 500 μm. (G-H) Western blot analysis showing the
apoptotic cleavage of PARP in MSC-5H-FC and T-5H-FC#1 adherent and tumorsphere cultures after the indicated dose–response (G) and
time-course (H) trabectedin treatments. I) Protein levels of γH2AX after the indicated trabectedin treatment in MSC-5H-FC and T-5H-FC#1
adherent and tumorsphere cultures. β-actin levels were used as loading control.
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cytotoxicity (Supplementary Figure S4, C and D). Moreover trabectedin
andCPTcombination is highly effective in boosting apoptotic PARPcleavage
and γH2AX levels in CSC-enriched tumorsphere cultures (Figure 6L)
Altogether these results suggest that the combination of trabectedin
and CPT has a synergistic cytotoxic effect on sarcoma initiating cells,
including their CSC subpopulations.
Discussion
In this work we aim to investigate the effect of trabectedin on
sarcoma-initiating. We previously found that tumorsphere cultures or
ALDHhigh cells isolated from our MRCLS model are enriched in
bona fide subpopulations of CSCs [37]. Here we show thattrabectedin is able to decrease survival, induce apoptosis and cause
DNA damage in these CSCs subpopulations as efficiently as in
unselected adherent cultures. To the best of our knowledge, this is the
first work describing the effect of trabectedin on sarcoma CSC
subpopulations. In other types of tumors it has been described that
trabectedin is able to induce apoptosis and G2/M cell cycle arrest and
to reduce tumorsphere growth in CSC subpopulations derived from
prostate cancer cell lines [43]. We also demonstrate that, unlike what
we previously reported for doxorubicin [38], trabectedin represses the
expression of multiple genes and pathways involved in the
development and maintenance of the CSC phenotype. Despite the
differential effects of trabectedin and doxorubicin on the expression of
genes related to the CSC phenotype, trabectedin treatment of
Figure 4. Trabectedin targets both ALDH1low and ALDH1high subpopulations. ALDH1low and ALDH1high subpopulations in T5H–Ocellswere
sorted by flow cytometry and expanded for 24 h prior to start the experimental procedures. (A) ALDEFLUOR assay showing the activity of
ALDH1 inALDH1low andALDH1high subpopulations just before starting trabectedin treatments. ALDH1 activitywas blockedwith the specific
inhibitor DEAB to establish the basal level. (B) Protein levels of the indicated factors in ALDH1low and ALDH1high subpopulations treated with
the indicated concentrations of trabectedin for 24 h. (C) Cell viability (WST1 assay) measured after the treatment of the subpopulations with
increasing concentrations of trabectedin for 72 hours. (D-E) ALDH1high and ALDH1low subpopulations were pre-treated with the indicated
concentrations of trabectedin for 24 h and assayed for soft agar colony formation (anchorage-independent growth) (D) and tumorsphere
formation (E). Representative images (left panels) and relative quantification of the cell growth (WST-1 assay; right panels) are shown. Scale
bars = 200 μm. Error bars represent the standard deviation of at least two independent experiments.
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advantage over previously reported doxorubicin treatment of these
xenografts [38] (Figure S3), thus reproducing the results observed in
phase III clinical trials [44]. These data suggest that the toxicity of
trabectedin may not be related with its ability to modulate
CSC-related gene expression. In any case, new strategies with a
further impact on CSC subpopulations are needed to improve the
therapeutic efficacy of trabectedin over the standard treatments.
Therefore, we aimed to find combination strategies that could improve
the anti-tumor effects of trabectedin on both CSC and non-CSC
subpopulations. We explored the combination of trabectedin with
another DNA damaging agent CPT. Interestingly, a system biology
approach showed a high degree of similarity between transcriptional
signatures induced by trabectedin and irinotecan in a model of
myelomonocytic leukemia, thus providing potential rationales to
combine these drugs to obtain synergistic antitumor effects [45].
Indeed, the combination of trabectedin and CPT derivatives has proven
anti-tumor synergistic effects in Ewing Sarcoma cells through a
mechanism by which cells become hypersensitive to CPT by the
trabectedin-induced down-regulation of EWS-FLI-1-mediated expres-
sion of the RecQ helicase Werner syndrome protein (WRN) [26]. In
addition, this combination also resulted highly effective in the
inhibition of a human rhabdomyosarcoma xenograft [28]. In 12
patients with advanced translocation-positive sarcomas, trabectedin
followed by irinotecan treatment showed promising results since the
treatment was well-tolerated and caused disease stabilization in five
patients with Ewing sarcoma and a partial response in a patient with
synovial sarcoma [46]. In another Ewing sarcoma patient, a similarcombination regimen also resulted in disease stabilization before
treatment-unrelated death occurred [47]. Moreover, the combination
of trabectedin with irinotecan or topotecan demonstrated synergistic
effects in ovarian clear cell carcinoma cells [48]. Altogether, trabectedin
plus CPT combination seems to be a valuable strategy against different
types of STS and possibly other solid tumors.
In this study, we proved that trabectedin plus CPT combination
exhibits a very strong synergism in a model of MRCLS-initiating cells.
Importantly, we also demonstrate that this combination is highly
effective in eliminating CSC subpopulations. By comparing WRN
expression in MSC-5H-GFP and MSC-5H-FC cells, we found that
FUS-CHOP expression did not induce an up-regulation of this helicase
(Figure S6A). However, treatment of MSC-5H-FC cells with
trabectedin or CPT produced a dose-dependent inhibition of WRN
protein levels. Moreover, the combination of both drugs induced a
deeper repression of WRN expression (Figure S6B). In line with these
results, it has been reported that CPT treatment may induces the
degradation of WRN and this effect is related with the sensitivity of
tumor cells to CPT [49]. These findings suggest that the profound
down-regulation of WRN induced by trabectedin plus CPT treatment
may play a role in the synergistic cytotoxic effect of this combination.
In addition, other mechanisms of synergism between trabectedin
and CPT may be acting in our sarcoma models and other types of
tumors. In this regard, other alkylating agents have been shown to
increase the anti-tumor activity of campthotecins [41,42]. Mecha-
nistically, the anti-tumor activity of alkylating agents seems to be in
part mediated by toposimerase I trapping and enhancement of
topoisomerase I cleavage complexes [42]. Interestingly, DNA
Figure 5. Trabectedin inhibits the growth of MRCLS sarcoma xenografts. Mice with established T-5H-FC#1 tumor xenografts were
randomly assigned to two different groups (n = 10 per group) and treated i.v. with saline buffer (control) or trabectedin at a dose of 0.15
mg/kg on days 0, 7, 14, and 18. (A) Curves representing the mean tumor volume of T-5H-FC#1 xenografts during the treatments. Drug
efficacy expressed as the percentage of TGI at day 13 is indicated. (B) Kaplan–Meier curves generated using the reaching of a tumor
volume of 1000 mm3 as end-point event. (C) Tumor weight (D) at the end of the experiment. (D) Body weights of mice during the
treatments. (E) H&E staining of formalin-fixed paraffin embedded T5H–FC#1-generated xenografts extracted from control and
trabectedin-treated mice. Mitotic cells (red arrows) are indicated. Scale bars = 50 μm. (F) Quantification of mitosis as the number of
mitotic figures per 10 high power fields (40×). (G) Tumor grade score according to a variant of the French Federation of Comprehensive
Cancer Centers system. Error bars represent the standard deviation and asterisks indicate statistically significant differences between
trabectedin-treated and control groups (*:P b .05, **:P b .005, ***:P b .0005; two-sided Student t test). The log-rank test P value was
used to estimate significant differences between control and drug treated groups in Kaplan–Meier analysis.
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topoisomerase I cleavage complexes at sites different to those observed
after CPT treatment [25]. Therefore, the combination could highly
increase the formation of DNA breaks, ultimately leading to
synergistic toxicity. Although the main mechanism of
trabectedin-induced toxicity seems to be independent of topoisom-
erase I activity [50], it is plausible that in combination with CPT, the
enhanced poisoning of this enzyme may become a relevant
anti-tumor mechanism. Since WRN play an important role in the
DNA damage response originated by topoisomerase I inhibition, the
down-regulation of WRN by trabectedin and CPT may cooperate to
increase the toxicity.
Another possible mechanism of synergy between both drugs may
involve the ability of trabectedin to interfere with the NER
mechanism by forming a ternary complex with DNA and the
ERCC Excision Repair 5 (EERC5) endonuclease which eventually
triggers the formation of DSBs [20]. The confluence of two different
mechanisms of DSB generation could result in the accumulation of
unresolved DNA damage, which may exceed the capacity of the cell
to cope with DNA damage, consequently triggering a synergistic
cytotoxic response.Conclusion
These data suggest that trabectedin could act as an anti-pluripotency
therapy able to effectively target both CSC and non-CSC populations
derived from sarcoma initiating cells. Moreover, their efficacy is
synergistically enhanced when combined with CPT, thus reinforcing
the rationale for the clinical testing of this combination in STS
sarcoma patients.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2017.03.004.
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Figure 6. Trabectedin and camptothecin combination shows synergistic cytotoxic effect. (A-B) Dose–response curves of cell viability
normalized to the solvent control at 72 h of treatment of MSC-5H-FC (A) or T-5H-FC#1 (B) cells with the indicated combination of drugs.
(C-D) Dose–response cell viability curves of MSC-5H-FC (C) or T-5H-FC#1 (D) where the trabectedin + CPT series were normalized to the
value observed after treatment with CPT alone. In this representation the effect of CPT alone is subtracted from the combination values,
thus, showing the shift in the IC50 of trabectedin due to the combination. (E-F) Combination index plots generated for six constant ratio
combinations of trabectedin and CPT (1:10) by the CompuSyn software according to the Chou-Talalay method. Most of the combinations
meet the criteria for strong (CI between 0.1 and 0.3) and very strong synergism (CI b0.1). The CI values for ED50, ED75 and ED90
combination doses as calculated by the median effect equation are shown. (G) Representative images of immunostaining experiments
showing the effect of 1-hour treatment with trabectedin and/or CPT combination in γH2AX foci formation in MSC-5H cells. Inset shows a
magnification of a representative cell. Scale bars = 50 μm. An enlarged color version of this panel is displayed as Figure S3B. (H)
Quantification of γH2AX foci performed by counting cells high levels of DNA damage (N10 foci). More than 200 cells were counted for
each condition. A similar set of experiments for T-5H-FC#1 cells is presented as Figure S4. (I) γH2AX, cleaved PARP and β-actin protein
levels after the treatment of adherent cultures of MSC-5H and T-5H-FC#1 cells for 24 hours with the indicated concentrations. (J-K)
MSC-5H-FC and T-5H-FC#1 cells were pre-treated with the indicated concentrations of trabectedin for 72 h and left to grow in
tumorsphere culture conditions for 10 days. Representative images (J) and relative quantification of the cell viability (WST-1 assay) (K) are
shown. Scale bars = 200 μm. (L) γH2AX, cleaved PARP and β-actin protein levels after the treatment of sphere cultures of T-5H-FC#1
cells for 24 hours with the indicated concentrations. Error bars represent the standard deviation of at least three independent
experiments.
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